Bliss GVS Pharma Ltd P/E Ratio

The P/E Ratio of Bliss GVS Pharma Ltd is 12.2 as of 25 Jul 9.00 AM .a1#The P/E Ratio of Bliss GVS Pharma Ltd changed from 15 on March 2019 to 15.6 on March 2024 . This represents a CAGR of 0.66% over 6 years. a1#The Latest Trading Price of Bliss GVS Pharma Ltd is ₹ 119.2 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.3 in 5 years. This represents a CAGR of -0.72%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.5. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Bliss GVS Pharma Ltd changed from ₹ 1856 crore on March 2019 to ₹ 1179 crore on March 2024 . This represents a CAGR of -7.28% over 6 years. a1#The Revenue of Bliss GVS Pharma Ltd changed from ₹ 195.67 crore to ₹ 187.77 crore over 9 quarters. This represents a CAGR of -1.81% a1#The EBITDA of Bliss GVS Pharma Ltd changed from ₹ 45.86 crore to ₹ 38.45 crore over 9 quarters. This represents a CAGR of -7.53% a1#The Net Pr of Bliss GVS Pharma Ltd changed from ₹ 27.48 crore to ₹ 22.11 crore over 9 quarters. This represents a CAGR of -9.21% a1#The Dividend Payout of Bliss GVS Pharma Ltd changed from 13.85 % on March 2019 to 10.34 % on March 2024 . This represents a CAGR of -4.75% over 6 years. a1#

Bliss GVS Pharma Ltd is an export-oriented pharmaceutical company. It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Bliss GVS Pharma has presence in antimalarial, antifungal, antibacterial, anti-inflammatory and antibiotic therapeutic segments. It is a leading player in the antimalarial branded formulations segment. Bliss GVS Pharma is the only EU-GMP certified suppositories manufacturer in India. The company has a dedicated the R&D Centre for development of Suppositories, Semi Solids and Oral Solids with an experienced Team of over 50 Scientists for formulation development and analytical method development and certified by the Department of Scientific & Industrial Research (DSIR), Government of India. Incorporated in 1984 as a private limited company under the name Bliss Chemicals & Pharmaceuticals India Ltd, the company commenced its business in 1985. In 1994 the company introduced a new pharmaceutical product VAGID.During the financial year ended 31 March 2014, Bliss GVS Pharma's R&D center, received approval from Government of India's Department for Scientific & Industrial Research (DSIR). During the year under review, the company invested in 51% share capital of Lifeon Labs Pvt Ltd. During the year under review, Bliss GVS Pharma faced challenges in Ghana, where delays in registration resulted in adverse regulatory action. However, the company took quick, corrective measures to resolve these issues. The business is now backing on track in Ghana. During the year ended 31 March 2015, Bliss GVS Pharma formed a new company Asterisk Lifesciences Limited as a wholly owned foreign subsidiary in United Kingdom for the purpose of facilitating registrations and marketing of pharmaceutical formulations in the European continent. During the financial year ended 31 March 2016, Bliss GVS Pharma continued to grow in various geographies in Kenya, Nigeria and France. Such growth was mainly achieved due to contract manufacturing and consistent focus on new product launch in Kenya and Nigeria. Bliss GVS Pharma continued to strengthen its operations and creation of robust Quality Manufacturing operations during the year ended 31 March 2017, The company's investment in managed healthcare services delivered encouraging results with the company procuring USD 111.40 mMillion contract from Aon. This presents a great platform for the unit to build on its recent success to successfully bid for other such contracts. During the year ended 31 March 2018, Bliss GVS Pharma divested three subsidiaries viz. Lifeon Labs Private Limited, Bliss Indasi Lifescience Private Limited and Shree Salespack Private Limited and one materially significant step down subsidiary Bliss GVS Healthcare Limited, Nairobi to focus on its core pharmaceutical operations, which have been a steady source of growth. As on 31 March 2019,the company has one domestic and 3 overseas subsidiaries. During the FY2020,the Company has completed the commissioning & qualification of Phase-I for its new state of the art multi-product facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the Company in terms of planned production capacity when completed. It is equipped with state-of-the-art process equipment & utilities with a large part of the manufacturing process automated for enhanced levels of productivity, efficiency & compliance while reducing manual intervention. The unit is spread on an overall area of about 200,000 sq. ft. and is intended to further augment the production capacities for the Company. The Company has 4 wholly owned subsidiaries and 3 step-down subsidiaries as on 31 March 2020. During the year, ECO Rich Cosmetics India Private Limited discontinued or ceased to be a step-down subsidiary of the Company consequent to loss of control. The Company's wholly owned subsidiary Bliss GVS Clinic HealthCare Pte. Ltd. situated at Singapore became a material subsidiary for the Company during the financial year 2019-2020.